Product Name:2-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidine

IUPAC Name:2-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidine

CAS:1052686-67-5
Molecular Formula:C11H17BN2O2
Purity:95%+
Catalog Number:CM128528
Molecular Weight:220.08

Packing Unit Available Stock Price($) Quantity
CM128528-50g in stock IJƿƿƿ
CM128528-100g in stock IJǤŗů

For R&D use only.

Inquiry Form

   refresh    

Product Details

CAS NO:1052686-67-5
Molecular Formula:C11H17BN2O2
Melting Point:-
Smiles Code:CC1=NC=C(C=N1)B1OC(C)(C)C(C)(C)O1
Density:
Catalog Number:CM128528
Molecular Weight:220.08
Boiling Point:
MDL No:MFCD12032615
Storage:

Category Infos

Pyrimidines
Pyrimidine, also known as 1,3-diazobenzene, is a heterocyclic compound with the chemical formula C4H4N2. Pyrimidine is formed by substituting 2 nitrogen atoms for 2 carbons in the meta-position of benzene. It is a diazine and retains its aromaticity. Derivatives of pyrimidine widely exist in organic macromolecular nucleic acids, and many drugs also contain pyrimidine rings. In nucleic acids, three nucleobases are pyrimidine derivatives: cytosine, thymine and uracil. There are a variety of pyrimidine-containing drugs on the market, most of which are kinase inhibitors.
Boronic Acids and Esters
Boronic acids and boronate esters are commonly used reagents in Suzuki–Miyaura coupling chemistry. Organoboron derivatives are common reagents for C–C bond formation, either through classical palladium-mediated transformations or through other newer coupling methods. Boronic esters and acids are potential intermediates in the manufacture of many active pharmaceutical ingredients (API).
Boronic Acid For Sale
Find trusted boronic acid for sale. Any requirements and problems can ask us at any time.

Column Infos

Voydeya
Voydeya (danicopan) has been approved in Japan for the treatment of paroxysmal nocturnal haemoglobinuria (PNH). Voydeya is the first drug in the class to be cleared for marketing anywhere in the world and has been licensed for use as an add-on therapy to C5 inhibitors, like its own Soliris (eculizumab) and Ultomiris (ravulizumab) products, in patients who don’t get a satisfactory response from C5 drugs alone. Voydeya (danicopan) is a first-in-class oral Factor D inhibitor. Voydeya has been granted Breakthrough Therapy designation by the US Food and Drug Administration and PRIority MEdicines (PRIME) status by the European Medicines Agency. Voydeya has also been granted Orphan Drug Designation in the US, EU and Japan for the treatment of PNH.

Related Products